ArticleFrontiers in pharmacology2018
The Effects of Ginsenoside Compound K Against Epilepsy by Enhancing the γ-Aminobutyric Acid Signaling Pathway.
Article in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 33 citations in OpenAlex.
- Natural Products in Epilepsy Treatment: From Traditional Medicine Towards Computational Drug Discovery.Current issues in molecular biology · 2026Review
- New advances in Traditional Chinese Medicine interventions for epilepsy: where are we and what do we know?Chinese medicine · 2025Review
- Geraniol Ameliorates Pentylenetetrazol-Induced Epilepsy, Neuroinflammation, and Oxidative Stress via Modulating the GABAergic Tract: In vitro and in vivo studies.Drug design, development and therapy · 2024Article
- The interplay between microbiota and brain-gut axis in epilepsy treatment.Frontiers in pharmacology · 2024Review
- Progress of Ginsenoside Rb1 in neurological disorders.Frontiers in pharmacology · 2024Review
- Advances in the biosynthesis and metabolic engineering of rare ginsenosides.Applied microbiology and biotechnology · 2023Review
- A narrative review on traditional Chinese medicine prescriptions and bioactive components in epilepsy treatment.Annals of translational medicine · 2023Review
- Article
- A narrative review of the pharmacology of ginsenoside compound K.Annals of translational medicine · 2022Review
- Neuroprotective Mechanisms of Ginsenoside Rb1 in Central Nervous System Diseases.Frontiers in pharmacology · 2022Review
- Neuroprotection of cannabidiol in epileptic rats: Gut microbiome and metabolome sequencing.Frontiers in nutrition · 2022Article
- The promising therapeutic potentials of ginsenosides mediated through p38 MAPK signaling inhibition.Heliyon · 2021Review
- Article
- Combination therapy of ginsenoside compound K and methotrexate was efficient in elimination of anaemia and reduction of disease activity in adjuvant-induced arthritis rats.Pharmaceutical biology · 2020Article
- Ginsenoside Compound K: Insights into Recent Studies on Pharmacokinetics and Health-Promoting Activities.Biomolecules · 2020Review
- Overexpressed microRNA-494 represses RIPK1 to attenuate hippocampal neuron injury in epilepsy rats by inactivating the NF-κB signaling pathway.Cell cycle (Georgetown, Tex.) · 2020Article
- The Effect of Protein-Rich Extract fromMolecules (Basel, Switzerland) · 2020Article
- Ginsenoside Rb1 regulates prefrontal cortical GABAergic transmission in MPTP-treated mice.Aging · 2019Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The imbalance between the GABA-mediated inhibition and the glutamate-mediated excitation is the primary pathological mechanism of epilepsy. GABAergic and glutamatergic neurotransmission have become the most important targets for controlling epilepsy. Ginsenoside compound K (GCK) is a main metabolic production of the ginsenoside Rb1, Rb2, and Rc in the intestinal microbiota. Previous studies show that GCK promoted the release of GABA from the hippocampal neurons and enhanced the activity of GABA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.